Radiation therapy for metastatic gastrointestinal cancers
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding radiation therapy to your current immunotherapy can help control cancer that has spread in the digestive system. It aims to improve symptoms and possibly slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a gastrointestinal cancer that has spread, such as cancer of the esophagus, stomach, liver, pancreas, or colon.
- You are currently receiving immunotherapy and your cancer has continued to grow despite it.
- You have between 1 and 5 areas of cancer that need radiation to relieve symptoms like pain, bleeding, or trouble swallowing.
- You must be able to receive both radiation and immunotherapy as decided by your doctors.
- You are at least 18 years old and expected to live more than 6 months.
- You are generally able to care for yourself (ECOG 0-2 or Karnofsky 50 or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination treatment for advanced or metastatic stomach cancer (that is MSS/pMMR and HER2-negative) that has not been treated before. The treatment combines a short course of radiation (targeted to lymph nodes) with first-line therapy and a PD-1 inhibitor (a type of immunotherapy) to see if it can help control the cancer and improve outcomes.
This trial compares two chemotherapy combinations, with or without an immunotherapy drug called nivolumab, for people with advanced stomach, esophagus, or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see which treatment works better and if adding immunotherapy helps.
This trial tests a combination of immunotherapy (a treatment that helps your immune system fight cancer) with radiation therapy for a certain type of stomach or gastroesophageal junction cancer that has a special genetic marker. The goal is to see if this combination is safe and effective.
This study tests a combination of targeted radiation (SBRT) and immunotherapy for people with esophageal cancer that has spread to a few spots in the body. The goal is to see if this approach helps control the cancer and improves your well-being.
This trial tests whether adding radiotherapy can help people with metastatic esophageal cancer that has already responded well to initial treatment with immunotherapy and chemotherapy. It may offer a way to improve outcomes for those whose cancer has not progressed after 2-4 cycles of first-line treatment.
This trial studies how to best target radiation for people with advanced esophageal cancer who are also getting immunotherapy. It aims to improve treatment planning to help patients live longer with fewer side effects.
Hear when a new Metastatic Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.